Ianalumab binds BAFF-R on B cells and, via its afucosylated IgG1 Fc, engages Fcγ receptors on effector cells to trigger ADCC and ADCP (NK cell–mediated lysis and macrophage phagocytosis), depleting BAFF-R–expressing cells; BAFF signaling blockade may also promote apoptosis.